Background & aim: Eradication of Helicobacter pylori (H. pylori.) has been reported as an effective strategy in the treatment of peptic ulcer and gastric mucosa-associated lymphoid tissue lymphoma. With the increasing frequency of antibiotic-resistant H. pylori, there is rising concern about the potential decline in the eradication rate. In the current study we aimed to valuated whether rebamipide could improve success rates of anti-H. pylori treatment and treat resistant cases of H. pylori.